These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30722017)

  • 41. ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study.
    Hua X; Li C; Pogue JM; Sharma VS; Karaiskos I; Kaye KS; Tsuji BT; Bergen PJ; Zhu Y; Song J; Li J
    JMIR Mhealth Uhealth; 2020 Dec; 8(12):e20525. PubMed ID: 33325835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.
    Karvanen M; Plachouras D; Friberg LE; Paramythiotou E; Papadomichelakis E; Karaiskos I; Tsangaris I; Armaganidis A; Cars O; Giamarellou H
    Antimicrob Agents Chemother; 2013 Jan; 57(1):668-71. PubMed ID: 23147733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
    Sandri AM; Landersdorfer CB; Jacob J; Boniatti MM; Dalarosa MG; Falci DR; Behle TF; Bordinhão RC; Wang J; Forrest A; Nation RL; Li J; Zavascki AP
    Clin Infect Dis; 2013 Aug; 57(4):524-31. PubMed ID: 23697744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.
    Yapa SWS; Li J; Patel K; Wilson JW; Dooley MJ; George J; Clark D; Poole S; Williams E; Porter CJ; Nation RL; McIntosh MP
    Antimicrob Agents Chemother; 2014 May; 58(5):2570-9. PubMed ID: 24550334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis.
    Falagas ME; Sideri G; Vouloumanou EK; Papadatos JH; Kafetzis DA
    Pediatr Infect Dis J; 2009 Feb; 28(2):123-7. PubMed ID: 19116601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
    Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
    Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous colistin use for infections due to MDR Gram-negative bacilli in critically ill paediatric patients: a systematic review and meta-analysis.
    Karageorgos SA; Bassiri H; Siakallis G; Miligkos M; Tsioutis C
    J Antimicrob Chemother; 2019 Sep; 74(9):2497-2506. PubMed ID: 31049586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion.
    Viel A; Henri J; Bouchène S; Laroche J; Rolland JG; Manceau J; Laurentie M; Couet W; Grégoire N
    Pharm Res; 2018 Mar; 35(5):92. PubMed ID: 29532176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.
    He H; Li JC; Nation RL; Jacob J; Chen G; Lee HJ; Tsuji BT; Thompson PE; Roberts K; Velkov T; Li J
    J Antimicrob Chemother; 2013 Oct; 68(10):2311-7. PubMed ID: 23749953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects.
    Mizuyachi K; Hara K; Wakamatsu A; Nohda S; Hirama T
    Curr Med Res Opin; 2011 Dec; 27(12):2261-70. PubMed ID: 21995648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.
    Kim EJ; Oh J; Lee K; Yu KS; Chung JY; Hwang JH; Nam EY; Kim HS; Kim M; Park JS; Song KH; Kim ES; Song J; Kim HB
    Ther Drug Monit; 2019 Feb; 41(1):102-106. PubMed ID: 30299430
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.
    Inparajah M; Wong C; Sibbald C; Boodhan S; Atenafu EG; Naqvi A; Dupuis LL
    Pharmacotherapy; 2010 Jan; 30(1):43-51. PubMed ID: 20030472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Different Component Contents of Colistin Methanesulfonate on the Pharmacokinetics of Prodrug and Formed Colistin in Human.
    Fan YX; Chen YC; Li Y; Yu JC; Bian XC; Li X; Li WZ; Guo BN; Wu HL; Liu XF; Wang Y; Xu XY; Hu JL; Wang JJ; Wu XJ; Cao GY; Wu JF; Xue CJ; Feng J; Zhang YY; Zhang J
    Pharm Res; 2021 Jan; 38(1):79-87. PubMed ID: 33496870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients.
    Xie YL; Jin X; Yan SS; Wu CF; Xiang BX; Wang H; Liang W; Yang BC; Xiao XF; Li ZL; Pei Q; Zuo XC; Peng Y
    Front Pharmacol; 2022; 13():967412. PubMed ID: 36105229
    [No Abstract]   [Full Text] [Related]  

  • 56. Determination of a dosage regimen of colistin by pharmacokinetic/pharmacodynamic integration and modeling for treatment of G.I.T. disease in pigs.
    Guyonnet J; Manco B; Baduel L; Kaltsatos V; Aliabadi MH; Lees P
    Res Vet Sci; 2010 Apr; 88(2):307-14. PubMed ID: 19945722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses.
    Zhao M; Wu XJ; Fan YX; Zhang YY; Guo BN; Yu JC; Cao GY; Chen YC; Wu JF; Shi YG; Li J; Zhang J
    Int J Antimicrob Agents; 2018 May; 51(5):714-720. PubMed ID: 29305956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.
    Forrest A; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Paterson DL; Li J; Silveira FP; Nation RL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring.
    Bode-Böger SM; Schopp B; Tröger U; Martens-Lobenhoffer J; Kalousis K; Mailänder P
    Int J Antimicrob Agents; 2013 Oct; 42(4):357-60. PubMed ID: 24011987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of intravenous colistin in children.
    Kumar PP; Giri SR; Shaikh FA; Panigrahy N; Chirla D
    Indian Pediatr; 2015 Feb; 52(2):129-30. PubMed ID: 25691180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.